Get the Stockscreener App
2.38
8.68%
0.19
After Hours:
2.39
0.01
+0.42%
Climb Bio Inc stock is traded at $2.38, with a volume of 797.75K.
It is up +8.68% in the last 24 hours and up +68.79% over the past month.
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.
See More
Previous Close:
$2.19
Open:
$2.21
24h Volume:
797.75K
Relative Volume:
1.97
Market Cap:
$161.28M
Revenue:
-
Net Income/Loss:
$-64.20M
P/E Ratio:
-1.107
EPS:
-2.15
Net Cash Flow:
$57,000
1W Performance:
+25.26%
1M Performance:
+68.79%
6M Performance:
+61.90%
1Y Performance:
+0.00%
1-Day Range:
$2.1701
$2.42
1-Week Range:
$1.93
$2.42
52-Week Range:
$1.05
$5.47
Climb Bio Inc Stock (CLYM) Company Profile
Name
Climb Bio Inc
Sector
Industry
Phone
1-866-857-2596
Address
20 WILLIAM STREET, WELLESLEY HILLS
Compare CLYM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLYM
Climb Bio Inc
|
2.38 | 142.98M | 0 | -64.20M | 57,000 | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Climb Bio Inc Stock (CLYM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-25 | Initiated | Robert W. Baird | Outperform |
| Jun-06-25 | Initiated | Oppenheimer | Outperform |
| May-22-25 | Initiated | BTIG Research | Buy |
| Dec-02-24 | Initiated | Leerink Partners | Outperform |
Climb Bio Inc Stock (CLYM) Latest News
Is Climb Bio, Inc. (CLYM) Outperforming Other Medical Stocks This Year? - Yahoo Finance
How to manage a losing position in Climb Bio Inc.Portfolio Update Report & Growth Oriented Trade Recommendations - Newser
Is Climb Bio Inc. reversing from oversold territoryJuly 2025 Fed Impact & Smart Investment Allocation Tips - Newser
Pattern recognition hints at Climb Bio Inc. upsideWeekly Trade Review & Entry Point Confirmation Signals - Newser
What moving averages say about Climb Bio Inc.Quarterly Performance Summary & Verified Chart Pattern Trade Signals - Newser
Is it time to cut losses on Climb Bio Inc.2025 Volatility Report & Stock Portfolio Risk Control - Newser
Will Climb Bio Inc. see short term momentumWeekly Trend Summary & Fast Entry High Yield Stock Tips - Newser
Evaluating Climb Bio Inc. with trendline analysisGap Up & Community Consensus Stock Picks - Newser
Heatmap analysis for Climb Bio Inc. and competitorsJuly 2025 Institutional & Fast Entry and Exit Trade Plans - Newser
Market reaction to Climb Bio Inc.’s recent newsJuly 2025 Rallies & Short-Term High Return Strategies - Newser
How to escape a deep drawdown in Climb Bio Inc.Oil Prices & Technical Confirmation Trade Alerts - Newser
Multi factor analysis applied to Climb Bio Inc.Stop Loss & Short-Term High Return Strategies - Newser
Climb Bio Inc: Buy, Hold, or Sell? Analysts Weigh In Amid Market Challenges - investchronicle.com
Analysts Set Climb Bio, Inc. (NASDAQ:CLYM) Target Price at $9.00 - Defense World
Using Python tools to backtest Climb Bio Inc. strategiesTrade Risk Report & Weekly Sector Rotation Insights - Newser
Will Climb Bio Inc. outperform the marketPortfolio Gains Summary & Expert Curated Trade Setups - Newser
Climb Bio Inc. stock daily chart insightsJuly 2025 Technicals & High Accuracy Trade Signal Alerts - Newser
Using data models to predict Climb Bio Inc. stock movementGap Down & Weekly Market Pulse Updates - Newser
Historical volatility pattern of Climb Bio Inc. visualizedJuly 2025 Selloffs & Consistent Income Trade Ideas - Newser
Climb Bio, Inc. (NASDAQ:CLYM) surges 12%; private equity firms who own 54% shares profited along with institutions - uk.finance.yahoo.com
Baird R W Upgrades Climb Bio (NASDAQ:CLYM) to “Strong-Buy” - Defense World
XTX Topco Ltd Acquires Shares of 27,660 Climb Bio, Inc. (NASDAQ:CLYM) - Defense World
Robert W. Baird Initiates Coverage on Climb Bio (NASDAQ:CLYM) - Defense World
Climb Bio Inc. Stock Support and Resistance Levels You Should KnowJuly 2025 Recap & Precise Swing Trade Alerts - Newser
Sentiment analysis tools applied to Climb Bio Inc.2025 Trading Volume Trends & Expert Approved Momentum Trade Ideas - Newser
Will Climb Bio Inc. stock recover after recent dropMarket Movement Recap & Community Driven Trade Alerts - Newser
Volatility clustering patterns for IGM Biosciences Inc.2025 Pullback Review & AI Forecasted Entry/Exit Points - Newser
Using economic indicators to assess BNY Mellon Strategic Municipals Inc. potential - Newser
Is Cingulate Inc. Equity Warrant showing signs of accumulationJuly 2025 Snapshot & AI Forecasted Entry/Exit Points - Newser
What MACD and RSI say about MET.PRAJuly 2025 Short Interest & Verified High Yield Trade Plans - Newser
What is Leerink Partnrs’ Forecast for Climb Bio Q3 Earnings? - Defense World
Historical volatility pattern of The Oncology Institute Inc. Equity Warrant visualized2025 Key Highlights & Precise Buy Zone Tips - Newser
What’s the recovery path for long term holders of Climb Bio Inc.July 2025 EndofMonth & Accurate Entry and Exit Point Alerts - Newser
Climb Bio Inc. Company Revenue and Profit Trends: A Deep DiveWeekly Trend Recap & High Accuracy Swing Trade Signals - Newser
Exit strategy if you’re trapped in Climb Bio Inc.Portfolio Value Summary & Daily Entry Point Alerts - Newser
How Resilient Is Climb Bio Inc. Stock During Economic DownturnsJuly 2025 Closing Moves & Precise Buy Zone Tips - Newser
Using RSI to spot recovery in Aflac IncorporatedWeekly Trade Analysis & Verified Momentum Watchlists - Newser
Climb Bio initiated with an Outperform at Baird on budoprutug potential - TipRanks
Baird Initiates Climb Bio at Outperform With $9 Price Target - MarketScreener
Statistical indicators supporting Climb Global Solutions Inc.’s strengthQuarterly Profit Report & Daily Profit Focused Screening - Newser
Climb Bio Reports Progress in Clinical Trials and Financial Stability - TipRanks
Can volume confirm reversal in Range Resources CorporationMarket Sentiment Review & Real-Time Stock Price Movement Reports - Newser
Climb Bio Inc Stock (CLYM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Climb Bio Inc Stock (CLYM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Pimblett Emily | SVP, Finance & CAO |
Jun 20 '25 |
Sale |
1.24 |
1,242 |
1,540 |
18,888 |
| Pimblett Emily | SVP, Finance & CAO |
Mar 20 '25 |
Sale |
1.31 |
1,199 |
1,571 |
15,130 |
| Pimblett Emily | CHIEF ACCOUNTING OFFICER |
Dec 19 '24 |
Sale |
2.02 |
1,235 |
2,495 |
11,329 |
| Pimblett Emily | CHIEF ACCOUNTING OFFICER |
Sep 20 '24 |
Sale |
8.18 |
1,191 |
9,741 |
7,564 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):